U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H17ClN2O3S
Molecular Weight 388.868
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AZD-1981

SMILES

CC(=O)NC1=CC=CC2=C1C(SC3=CC=C(Cl)C=C3)=C(C)N2CC(O)=O

InChI

InChIKey=JWYIGNODXSRKGP-UHFFFAOYSA-N
InChI=1S/C19H17ClN2O3S/c1-11-19(26-14-8-6-13(20)7-9-14)18-15(21-12(2)23)4-3-5-16(18)22(11)10-17(24)25/h3-9H,10H2,1-2H3,(H,21,23)(H,24,25)

HIDE SMILES / InChI

Molecular Formula C19H17ClN2O3S
Molecular Weight 388.868
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23827726

AZD-1981, developed by AstraZeneca, is a potent (binding IC50 of 4nM), fully reversible, functionally non-competitive antagonist of human CRTh2. It blocks agonist-induced human eosinophil CD11b expression, shape change (including in whole blood), and chemotaxis as well as an basophil shape change and Th2-cell chemotaxis at IC50's of 8.5-50nM. Potency is similar across species as is plasma protein binding (~97%). AZD-1981 is a weak (10s of μM) inhibitor in vitro of CYP2C9, OATP1B1 and UGT1A1 as well as an inducer of CYP3A4. AZD-1981 was well tolerated and no safety concerns were identified.There was no beneficial clinical effect of AZD-1981, at a dose of 1000 mg twice daily for 4 weeks, in patients with moderate to severe COPD. AZD-1981 has being discontinued for asthma and chronic obstructive pulmonary disease. AstraZeneca is collaborating with Johns Hopkins University for the development of AZD-1981 in the treatment of chronic idiopathic urticaria. It is in phase II clinicals studies for the treatment of Urticaria.

CNS Activity

Curator's Comment: AZD1981 has low CNS penetration and, thus, is probably not suitable for a CNS indication

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
4.3 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
9030 nM
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AZD-1981 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
18900 nM × h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AZD-1981 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Substituted indole-1-acetic acids as potent and selective CRTh2 antagonists-discovery of AZD1981.
2011 Nov 1
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.
2014 Jun
Patents

Sample Use Guides

In Vivo Use Guide
AZD-1981 has been administered orally in healthy volunteers (single oral dose up to 4,000 mg; multiple doses up to 2,000 mg twice daily [BID] for 2 wks), asthma or COPD patients (up to 100 mg, BID for 4 wks), and asthmatics (up to 400 mg BID for 12 wks).
Route of Administration: Oral
AZD-1981 inhibits DK-PGD2-induced CD11b expression in human eosinophils with IC50 of 10 nM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:47:55 GMT 2023
Edited
by admin
on Fri Dec 15 19:47:55 GMT 2023
Record UNII
2AD53WQ2CX
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AZD-1981
Common Name English
1H-INDOLE-1-ACETIC ACID, 4-(ACETYLAMINO)-3-((4-CHLOROPHENYL)THIO)-2-METHYL-
Common Name English
AZD1981
Common Name English
AZD 1981 [WHO-DD]
Common Name English
Code System Code Type Description
PUBCHEM
11292191
Created by admin on Fri Dec 15 19:47:55 GMT 2023 , Edited by admin on Fri Dec 15 19:47:55 GMT 2023
PRIMARY
SMS_ID
100000174982
Created by admin on Fri Dec 15 19:47:55 GMT 2023 , Edited by admin on Fri Dec 15 19:47:55 GMT 2023
PRIMARY
ChEMBL
CHEMBL1914489
Created by admin on Fri Dec 15 19:47:55 GMT 2023 , Edited by admin on Fri Dec 15 19:47:55 GMT 2023
PRIMARY
EPA CompTox
DTXSID901025620
Created by admin on Fri Dec 15 19:47:55 GMT 2023 , Edited by admin on Fri Dec 15 19:47:55 GMT 2023
PRIMARY
FDA UNII
2AD53WQ2CX
Created by admin on Fri Dec 15 19:47:55 GMT 2023 , Edited by admin on Fri Dec 15 19:47:55 GMT 2023
PRIMARY
DRUG BANK
DB11946
Created by admin on Fri Dec 15 19:47:55 GMT 2023 , Edited by admin on Fri Dec 15 19:47:55 GMT 2023
PRIMARY
CAS
802904-66-1
Created by admin on Fri Dec 15 19:47:55 GMT 2023 , Edited by admin on Fri Dec 15 19:47:55 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY